NEW YORK, Feb. 25 (GenomeWeb News) - The US Food and Drug Administration has used a quantitative-based modeling and simulation program designed by Pharsight to help it design an end-of-Phase IIa trial for an anti-HIV drug, Pharsight said today.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.